Latest Intelligence on Therapy Area

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wilex/4SC: cancer research collaboration should bear fruit

The German biotech companies aim to accelerate the development of products related to Wilex's lead compound WX-293. Both companies should benefit from the deal: Wilex will gain access to the latest targeted drug development technologies, while 4SC will directly increase its revenues through milestone payments.

Published By Datamonitor
14 Jan 2002
Expert View
Expert View

Who will plug the brain metastases treatment gap?

One in 10 cancer patients fall foul of brain metastases - a patient population as large as that of lung or breast cancer. Despite this demand - and although many drugs have been shown to have activity in brain metastases - none are commonly used. This leaves a market with great unmet need and little competition - but who will fill the hole?

Published By Datamonitor
01 Feb 2002
Expert View
Expert View

What will stem from stem cell research

Published By Datamonitor
12 Jan 2001
CommentWire
CommentWire

Watson Pharmaceuticals: Gelnique to benefit from first-to-market status

Watson Pharmaceuticals's Gelnique is the first gel to be approved by the FDA for the treatment of overactive bladder, and provides an advantageous side-effect profile over current oral anticholinergic and patch treatments. As a result, Datamonitor expects Gelnique to be beneficial for a niche population and to generate $124m in 2016.

Published By Datamonitor
28 Jan 2009
ResearchWire
ResearchWire

VZV: combination products will take over the market

Published By Datamonitor
04 Jun 2001
CommentWire
CommentWire

Vysis: a major player in the diagnostics market

Published By Datamonitor
06 Aug 2001
CommentWire
CommentWire

Vitamin C: benefits of supplements still in question

Published By Datamonitor
05 Oct 2000
CommentWire
CommentWire

VIRxSYS: hope for HIV gene therapy

A genetically engineered form of the HIV virus has shown promising results in a small clinical trial, achieving some viral load reduction and immune system recovery in four out of five treated patients. This new approach, while still in its early stages, may fulfill major unmet needs in the disease, and could even have potential as a preventative measure.

Published By Datamonitor
08 Nov 2006
CommentWire
CommentWire

ViroPharma: cold cure may prove hard to justify

The common cold is certainly an attractive condition to target, considering its prevalence and its economic cost. However, Picovir's effect is to speeds the recovery rate, which is extremely hard to quantify in trials. As a result, it will be hard to justify its reimbursement. Preventative common cold drugs have a much greater potential.

Published By Datamonitor
20 Mar 2002
CommentWire
CommentWire

Virco: looking into the future of AIDS therapy

Published By Datamonitor
17 Jul 2001

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.